The biotech sector saw a significant run-up last month, but for at least one analyst, questions remain about what the second half holds. Share this page
About the Author
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Network and Share
Also from thinkBiotech
Translator
